Track Annovis Bio, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Annovis Bio, Inc. ANVS · Stock Open Annovis Bio, Inc. in new tab

1.74 USD
Add to portfolio
EPS
-1.71
P/B
16.82
ROE
-301.13
Beta
1.24
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 18, 2026
EPS-1.71
Book Value0.11
Price to Book16.82
% Insiders8.255%
Estimates
Forward P/E-2.09
Forward EPS-0.89

DCF Valuation

Tweak assumptions to recompute fair value for Annovis Bio, Inc. (ANVS)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Annovis Bio, Inc. Analysis (ANVS)

United States Health Care Stock

Is Annovis Bio, Inc. a good investment? Annovis Bio, Inc. (ANVS) is currently trading at 1.74 USD.

Earnings Schedule: Annovis Bio, Inc. is expected to release its next earnings report on Aug. 18, 2026. The market consensus estimate for Forward EPS is -0.89.

Investor FAQ

Does Annovis Bio, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Annovis Bio, Inc.?

Annovis Bio, Inc. is classified as a Stock.

When is the next earnings date?

The next earnings date is projected to be Aug. 18, 2026. The company currently has a trailing EPS of -1.71.

Company Profile

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

Trades
No dividend information available for this instrument.

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion